nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-FF497927·Framework v5.0·Pipeline v0.4·Evaluated 15 Jun 2026·OECD: 3.1 Basic medicine·Subfield: Genetics·Basis: Full text·Type: Systematic review or meta-analysis

Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Grammatikopoulou et al.Grammatikopoulou, Gkiouras, Theodoridis et al.·2018·Nutrients·10.3390/nu10111737 ↗

In brief

A methodologically careful curcumin meta-analysis whose conservative rare-event correction usefully tempers enthusiasm, constrained by an evidence base of only three small, heterogeneous trials.

ReliabilityCaveats3 of 4 checks completeRead the 2 entries ↓
Abstract

Curcumin has demonstrated anti-inflammatory properties and has been investigated as an adjuvant therapy of ulcerative colitis (UC). The scope of this study was to systematically review and meta-analyze the efficacy of oral curcumin administration as an adjuvant therapy of UC. MEDLINE, Cochrane/CENTRAL, ClinicalTrials.gov, WHO-ICT Registry, EMBASE and grey literature were searched for relevant randomized controlled trials (RCTs). The primary outcome was clinical remission (attainment) and the secondary outcome was clinical response (maintenance/failure). Risk of bias was assessed with the Cochrane tool. Odds ratios (OR) were calculated with a Mantel-Haenszel (M-H) random effects model and with a beta-binomial (B-B) random effects model when zero events/cells occurred. Four RCTs met the criteria, but one was removed from the analyses due to inconsistency in protocol details. With the M-H method, treatment with curcumin was significantly superior to placebo in attaining remission in the per-protocol (PP) analysis (OR = 5.83, 95%CI = 1.24⁻27.43), but not in the intention-to-treat (ITT) analysis (OR = 4.33, 95%CI = 0.78⁻24.00). However, with the more accurate B-B method, both analyses were insignificant (for PP OR = 4.26, 95%CI = 0.59⁻31.00, for ITT OR = 3.80, 95%CI = 0.55⁻26.28). Based on the current available evidence, oral curcumin administration does not seem superior to placebo in attaining remission in patients with UC. Future RCTs should be planned more cautiously with sufficient size and adhere to the ITT analysis in all outcomes.

Strengths · Limitations

Strengths

#methodological rigour

Conservative rare-event method drives conclusion

Supplementing the Mantel-Haenszel model with a beta-binomial random effects model for zero-event cells correctly dissolves an apparent per-protocol significance, and the conclusion follows the more conservative result rather than the superficially positive one.

↳ Methods §2.6; Results §3.3

#reporting

Transparent, well-justified trial exclusion

The exclusion of the Banerjee trial is documented with specific registry-versus-results discrepancies in intervention duration, dose, and outcome measures, demonstrating reproducible quality control.

↳ Results §3.2

#positioning

Honest engagement with competing evidence

The discussion directly compares its findings against a concurrent meta-analysis and identifies specific methodological differences, including that study's pooling of enema trials and failure to address rare-event false significance.

↳ Discussion §4

Limitations

#contribution

Thin and heterogeneous evidence base

The meta-analysis rests on only three small RCTs with high heterogeneity (I2=73% for ITT) and heterogeneous dosing from 450 mg to 3 g daily, precluding subgroup analyses and definitive conclusions.

↳ Results §3.3; Discussion §4

#methodological rigour

Incomplete reporting against 2019 standards

Risk-of-bias terminology mixes RoB 2.0 with older high/unclear/low categories, no outcome-level GRADE certainty summary is presented, and the post-protocol search expansion is described narratively without a reproducible updated strategy.

↳ Methods §2.5; Discussion §4

#methodological rigour

No sensitivity analysis for key exclusion

Because excluding the Banerjee trial materially shapes the pooled estimates, the absence of a sensitivity analysis including and excluding it under explicit rules weakens the robustness of the synthesis.

↳ Results §3.2

Does this match your read? Add your assessment ↓

Nabu Commentary

The adjudicated scores reflect a synthesis that is methodologically aware but evidentiarily thin. The strongest feature is the use of a beta-binomial model to correct biased continuity correction for zero-event cells, which dissolves an apparent per-protocol benefit and anchors the cautious null conclusion (Methods §2.6, Results §3.3). Methodological Rigour scoring was tempered by reporting deficiencies that fall short of 2019 systematic-review norms, including inconsistent risk-of-bias terminology, an absent outcome-level GRADE summary, a non-reproducible post-protocol search expansion, and no sensitivity analysis around the influential trial exclusion (Methods §2.5, Results §3.2, Discussion §4). Impact potential rests primarily on cumulative-evidence value, with two ongoing trials identified as a baseline for future synthesis, while the three-RCT base and high heterogeneity (I2=73% ITT) cap actionability. The conclusion is appropriately framed as insufficient evidence rather than evidence of no effect.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.4±0.1

Contribution
3.3

The synthesis makes a genuine but bounded contribution by restricting to oral curcumin RCTs in UC and showing that statistical significance depends on rare-event handling, with the apparent per-protocol benefit disappearing under the beta-binomial method. The contribution is limited by a three-RCT evidence base that prevents definitive conclusions.

Results §3.3; Discussion §4

with the B-B method of calculating the OR, none of the above-mentioned analyses were significant

Methodological Rigour
3.3

Core methodology is competently executed: comprehensive multi-database search, duplicate screening and extraction, random effects modelling, and a beta-binomial supplement to correct biased continuity correction for zero-event cells. Reporting gaps temper the score, including inconsistent RoB 2.0 terminology, an absent outcome-level GRADE certainty summary, a non-reproducible post-protocol search expansion, and no sensitivity analysis around the influential Banerjee exclusion.

Methods §2.5-2.6; Results §3.2-3.3

RevMan applies a continuity correction... and this analysis has been showed to be biased

Reporting
3.8

The argument flows clearly from question to search and eligibility to the transparent Banerjee exclusion rationale and dual ITT/PP analysis, with appropriately restrained conclusions. Minor imprecision arises from mixed RoB terminology and an assertive abstract framing of the B-B method as more accurate without explanation.

Abstract; Methods §2; Results §3.2

absence of evidence is not evidence of absence

Positioning
3.4

The paper situates itself in the small curcumin/UC literature, distinguishes oral from enema delivery, and engages directly with a competing meta-analysis to identify its methodological pitfalls. Contextual integration is incomplete by 2019 norms, with GRADE invoked but no foregrounded outcome-level certainty synthesis and limitations dispersed rather than consolidated.

Discussion §4

those authors did not control for the false-significant results appearing when rare events exist

Lower confidence on Positioning — domain match limited.

Reliability

Caveats3 of 4 checks


Internal CoherenceNoted

The synthesis is largely internally consistent across abstract, methods, and results, with consistent OR/CI values and transparent documentation of the Banerjee exclusion. Two reporting watch-outs appear: the risk-of-bias method names RoB 2.0 but applies older high/unclear/low risk terminology, and the post-protocol search expansion is described narratively without a reproducible updated search strategy.

Research ConductNoted

Protocol registration (PROSPERO CRD42018098996) and duplicate screening/extraction support basic review conduct. No conflict-of-interest or funding statement is visible in the supplied text, and the disclosed protocol deviation is not fully operationalised in an updated methods record.

Flags: 1 declared / 5 total

Reference IntegrityPending

Not yet checked.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceSynthesis
Route to useNamed
AdvanceConsolidates
BeneficiariesSmall
CitationsFWCI 5.2
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Only three small heterogeneous RCTs with rare events were pooled, and the authors themselves call for larger confirmatory trials before firm conclusions.

From the paper
“guide clinicians towards/against curcumin supplementation in patients with UC”

The conclusion names clinicians as the actors who would use the pooled evidence to decide on curcumin supplementation in UC patients.

Pathway

Gastroenterologists and IBD clinicians would use pooled evidence to decide whether to add oral curcumin to UC patients' maintenance therapy.

Barrier

Small, heterogeneous RCTs with rare events, varying curcumin doses and unknown purity mean larger, standardized trials are needed before clinicians can be guided.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis

    Milad Sabzevary-Ghahfarokhi, Mojtaba Shohan, Hedayatollah Shirzad, et al. · 2018 · Basic medicine

    Primary claim

    Oxidative stress in inflamed colonic tissue can induce Nrf2 gene expression. The performance of Nrf2 transcription factor may lead to the induction of GST-A4 and PRDX1.

    Unsupported
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. Curcumin for maintenance of remission in ulcerative colitis

    Kumar, Ahuja, Sankar, et al. · 2012 · Clinical medicine

    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  3. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials

    Coelho, Romi, Ferreira, et al. · 2020 · Clinical medicine

    Evidence Score
    3.1±0.1
    Reliability
    Caveats

How the rubric works →